Gerresheimer Reports Revenue Growth and Stable Adjusted EBITDA in the Third Quarter of 2026 

Gerresheimer AG

/ Key word(s): Quarter Results/9 Month figures

Gerresheimer Reports Revenue Growth and Stable Adjusted EBITDA in the Third Quarter of 2026 

30.10.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Gerresheimer Reports Revenue Growth and Stable Adjusted EBITDA in the Third Quarter of 2026 

  • Preliminary Q3 Results: Revenue EUR 605 million; adjusted EBITDA EUR 103 million
  • Preliminary 9M Results: Revenue EUR 1.7 billion; adjusted EBITDA EUR 272 million
  • Stronger Q4 2026 expected in line with guidance
  • Preparations for the completion of the PPP sale

Duesseldorf, October 30, 2026. Gerresheimer, an innovative systems and solutions provider and global partner to the pharma, biotech, and cosmetics industries, today released preliminary results for the third quarter of 2026 and the first nine months of financial year 2026. Revenue, including the business units currently in the sales process, rose by 8% year-over-year to EUR 605 million in the third quarter of 2026 (Q3 2025: EUR 560 million, adjusted). Adjusted EBITDA reached EUR 103 million (Q3 2025: EUR 106 million, adjusted), remaining stable at the same level as in the previous year’s quarter. In the first nine months of the financial year, revenue, based on preliminary figures, was approximately at the previous year’s level at EUR 1.7 billion (9M 2025: EUR 1.7 billion, adjusted). Adjusted EBITDA, at EUR 272 million (9M 2025: EUR 331 million, adjusted), fell short of the previous year’s period due to inventory reductions and weaker performance in the Tubular Glass Europe and Moulded Glass business. With an adjusted EBITDA margin of 17.1% in the third quarter of 2026 (Q3 2025: 19.0%, adjusted), the adjusted EBITDA margin for the first nine months totaled 15.9% (9M 2025: 19.4%, adjusted). Revenue performance in the third quarter and the first nine months of 2026 was positively influenced primarily by the Containment & Delivery Systems division, driven by higher demand for drug delivery devices. Looking ahead to the remainder of financial year 2026, Gerresheimer expects a stronger fourth quarter with further earnings improvement, in line with its guidance. Following the successful completion of the Centor sale, Gerresheimer is now moving forward with the completion of the sale of the Primary Packaging Plastics business (PPP). The closing preparations are progressing well. As a result, the transaction is currently expected to close already in the first quarter of 2027.    

“Revenue growth in the third quarter of 2026, stable adjusted EBITDA compared to the same quarter last year, and a substantial improvement in our financial situation resulting from the successful completion of the Centor sale in October demonstrate the progress of our transformation,” said Wolf Lehmann, CFO of Gerresheimer AG. “The next milestones will be the closing of the sale of the Primary Packaging Plastics business and a comprehensive refinancing.” 

Containment & Delivery Systems: Drug Delivery Devices Drive Growth
The Containment & Delivery Systems division increased revenue and earnings in both the third quarter and the first nine months of 2026. According to preliminary figures and including the business units currently in the sales process, revenue in the first nine months of 2026 totaled approximately 917 million EUR (9M 2025: 876 million EUR, adjusted), of which the third quarter of 2026 contributed approximately 313 million EUR (Q3 2025: EUR 286 million, adjusted). Adjusted EBITDA rose to EUR 211 million in the first nine months of 2026 (9M 2025: EUR 194 million, adjusted), with the third quarter of 2026 contributing approximately EUR 77 million (Q3 2025: EUR 64 million, adjusted). The adjusted EBITDA margin was 23.9% in the first nine months (9M 2025: 22.2%, adjusted). The adjusted EBITDA margin of 24.5% in the third quarter (Q3 2025: 22.3%) contributed substantially to this improvement. The division benefited from rising demand for drug delivery devices. In recent years, Gerresheimer had invested in expanding production capacity in this division. The ramp-up of production is now leading to increasing revenue and earnings contributions.

Primary Injectable Solutions: Business stabilized in Q3
According to preliminary figures, the Primary Injectable Solutions division generated revenues of EUR 335 million in the first nine months of 2026 (9M 2025: EUR 360 million, adjusted), of which EUR 123 million was generated in the third quarter of 2026 (Q3 2025: EUR 114 million, adjusted). Adjusted EBITDA amounted to EUR 32 million (9M 2025: EUR 69 million, adjusted), of which the division generated EUR 15 million in the third quarter of 2026 (Q3 2025: EUR 19 million, adjusted). The adjusted EBITDA margin for the first nine months of 2026 totaled 9.5% due to the significantly weaker first half of the year (9M 2025: 19.3%, adjusted). Here, too, the third quarter of 2026, with an adjusted EBITDA margin of 12.5% (Q3 2025: 16.8%, adjusted) demonstrated the stabilization of the business, even though revenue, earnings, and the adjusted EBITDA margin for the first nine months were collectively below the previous year’s period. As part of the transformation program, measures are currently underway to improve capacity utilization and competitiveness in the Tubular Glass business.

Moulded Glass: Revenue stabilized in Q3; earnings impacted by inventory reduction
According to preliminary figures, the Moulded Glass division generated revenues of EUR 479 million in the first nine months of 2026 (9M 2025: EUR 492 million, adjusted), of which EUR 169 million was generated in the third quarter of 2026 (Q3 2025: EUR 165 million, adjusted). Adjusted EBITDA amounted to EUR 52 million (9M 2025: EUR 91 million, adjusted), of which the division generated EUR 17 million in the third quarter of 2026 (Q3 2025: EUR 29 million, adjusted). The adjusted EBITDA margin totaled 10.9% in the first nine months of 2026 (9M 2025: 18.6%, adjusted), whereby the adjusted EBITDA margin in the third quarter at 10.2% (Q3 2025: 17.4%, adjusted) was below the overall margin. In a weaker market environment, the Moulded Glass division reported lower revenue. In addition, inventory levels were reduced as part of cash management initiatives, which further lowered capacity utilization and had a negative impact on adjusted EBITDA. In this division as well, Gerresheimer has initiated measures to improve performance as part of its transformation program. For example, the Moulded Glass plant in Chicago Heights, USA, was closed in September 2026. 

Gerresheimer expects to publish its Q3 Quarterly Statement, containing the final figures for the third quarter and the first nine months of financial year 2026, in December 2026.

About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. The Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com

 

Contact Gerresheimer

Media  
Jutta Lorberg
Group Senior Director
Communication & Marketing
T +49 211 6181 264
jutta.lorberg@gerresheimer.com
Dersim Korkmaz
Manager Corporate Communication
T +49 211 6181 296
dersim.korkmaz@gerresheimer.com
 
Investor Relations
 
Guido Pickert
Vice President Investor Relations
T +49 211 6181 220
gerresheimer.ir@gerresheimer.com
 


30.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Gerresheimer AG
Peter-Müller-Str. 3
40468 Duesseldorf
Germany
Phone: +49-(0)211/61 81-00
Fax: +49-(0)211/61 81-121
E-mail: gerresheimer.ir@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 5299006GD4UWSYZOKC28
EQS News ID: 2424748

 
End of News EQS News Service

2424748  30.10.2026 CET/CEST

Chinese medical AI model wins top state science award as sectoral “ChatGPT moment” arrives

EQS Newswire / 30/10/2026 / 12:35 UTC+8

Results have recently been released for the final of the National Healthcare Security AI Image Recognition Contest. The contest, organised by China’s National Healthcare Security Administration, was built around real-world clinical imaging requirements. A total of 1,332 teams across China participated. Drawing on Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS)’s proprietary iMedImage®, the world’s first cross-modal foundation model, and its iMedLoop™ medical imaging AI R&D and production acceleration platform, a team from the Second Affiliated Hospital of Guangxi University of Chinese Medicine developed a CT diagnostic model for kidney cancer to claim first prize in the contest, while a breast cancer X-ray diagnostic model built by the First Affiliated Hospital of Guangxi Medical University secured second prize.

These remarkable results further validate DIAGENS’ technological leadership in the global medical AI sector and the broad applicability of its solutions.

In China, clinicians have taken center stage in the field of medical AI, with a domestic foundational technology stack enabling cross-modal applications to claim top awards. DIAGENS translated sophisticated R&D capabilities into foundations and tooling accessible to clinical teams, enabling clinicians to evolve from AI end-users into AI creators. The “ChatGPT moment” for medical imaging has arrived.

 

Foundation model: resetting the starting point for AI-driven medical innovation

Clinical specialists understand disease pathology best and grasp most clearly the pain points to resolve in real-world clinical workflows. For years, technical barriers spanning data processing, algorithm development, model training, evaluation and deployment have prevented vast pools of clinical expertise from translating directly into AI systems.

DIAGENS has rewritten this R&D pathway. Founded in 2016, the Hong Kong-listed artificial intelligence firm is recognised as the world’s first publicly listed company focused on medical imaging foundation models. It specialises in artificial intelligence and biomedicine, and aims to build a global industrialization platform for medical imaging AI. Centered on its self-developed iMedImage® medical imaging foundation model, the company provides a shared development backbone for specialised disease models. With 104 billion parameters, the model was pre-trained on 80 million clinical imaging studies. It delivers multi-modal compatibility across CT, X-ray, MRI, and ultrasound. Model support was available across 26 clinical specialties and over 4,000 disease scenarios. New clinical tasks can be adapted atop this existing foundation, reducing redundant effort associated with development from scratch.

On this basis, DIAGENS links data generation, model training, unified evaluation, deployment and application feedback via its iMedLoop™ medical imaging AI R&D and production acceleration platform, forming an integrated closed-loop R&D and production pipeline. Powered by iMedImage® and iMedLoop™, clinicians define tasks, set benchmarks and participate in development around real clinical challenges. The mature foundation and platform provide the capacity to tackle intricate technical and engineering challenges.

This framework packages DIAGENS’ long-accumulated technical expertise into an accessible platform, returns control of innovation to clinical teams, and supports disease specialists in leading innovation in medical AI.

 

National contest validation: proving the industrial rollout pathway for medical AI

The strong performance of the kidney cancer CT-based and mammography X-ray detection projects led by frontline clinicians at this contest stands as real-world proof of DIAGENS’ multimodal foundation capabilities and industrial innovation framework, demonstrated on a national professional stage.

Beyond the contest, this underlying technology stack has already undergone scaled rollout across clinical practice. Built on the iMedImage® medical imaging foundation model, DIAGENS has extended the capability frontier of medical imaging AI across diverse imaging modalities. CT, X-ray, MRI and ultrasound, alongside karyotyping and cytomorphology studies, all draw on the same foundational backbone and R&D-to-production pipeline. To date, DIAGENS has delivered a cumulative total of 158 model projects in partnership with 99 hospitals — 65 of which are Grade III Class A hospitals — spanning 43 anatomical sites and 61 disease categories.

This unified underlying capability spans multiple imaging modalities to support an ongoing stream of distinct diseases and clinical tasks. The industrialized framework enables batch development of high-performance specialist AI tools. DIAGENS continues to roll out its leading capabilities across further niche medical imaging verticals.

 

China’s new approach: ushering in the “ChatGPT moment” for global medical AI

ChatGPT redefined how people interact with AI, unlocking access to powerful AI capabilities for broader user groups. DIAGENS is reshaping how medical AI is developed. Its foundation model and R&D platform cut development hurdles for specialty-specific models, enabling more clinical specialists to shift from AI end-users to AI creators.

When clinicians can build AI models without writing code themselves, the scope for clinical innovation broadens substantially. Clinicians across diverse specialties can pursue research around their own clinical challenges, test hypotheses, translate specialist experience into a rich ecosystem of AI models, and distil clinical wisdom into reusable, deployable medical AI capabilities. This technical pathway rooted in Chinese practice widens the community of medical AI builders and expands the pool of beneficiaries of these innovations.

Powering multi-modal innovation, this industrial framework delivers on the “one foundation for thousands of models” paradigm — marking the arrival of the “ChatGPT moment” in medical imaging. DIAGENS leverages its homegrown proprietary technology to lead a global shift in the production of medical imaging AI.

 

30/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG continues its growth in the third quarter of 2026, driven by higher average room rates and strong activity at its flagship properties

AEVIS VICTORIA SA

/ Key word(s): 9 Month figures

AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG continues its growth in the third quarter of 2026, driven by higher average room rates and strong activity at its flagship properties

30.10.2026 / 07:00 CET/CEST


Press release

Interlaken, 30 October 2026

AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG continues its growth in the third quarter of 2026, driven by higher average room rates and strong activity at its flagship properties

MRH Switzerland AG, the hotel division of AEVIS VICTORIA SA, continued to grow over the first nine months of 2026. Revenue reached CHF 159.5 million, an increase of 1.3% compared to the same period in 2025. The third quarter confirmed the resilience of business activity, with particularly strong acceleration in September.

As of 30 September 2026, accommodation revenue increased by 1.8% to CHF 95.7 million. The average daily room rate rose by 5.4% to CHF 607, while revenue per available room (RevPAR) increased by 5.1% to CHF 348. The occupancy rate remained stable at 57.4%.

This performance confirms MRH Switzerland’s ability to capitalise on its upscale offering and pursue its strategy of qualitative growth, prioritising improvements in average room rates and revenue per available room.

Particularly positive momentum in the third quarter
This trend was particularly pronounced in September, with revenue of CHF 16.3 million, up 9.2% compared to September 2025. The average daily room rate reached CHF 488, an increase of 17.9%, while RevPAR rose by 14.3% to CHF 295.

Several flagship properties contributed to this momentum. The Victoria-Jungfrau Grand Hotel & Spa in Interlaken recorded revenue of CHF 43.9 million over the first nine months, up 3.5%, with a 6.6% increase in the average daily room rate. La Réserve Eden au Lac Zurich reported revenue growth of 4.4%, while AlpenGold Hotel Davos achieved an increase of 10.1%.

Outlook
Following a significant investment cycle across its properties, MRH Switzerland continues its strategy of enhancing the value of its hotel portfolio, building on the quality of its assets, their positioning in leading destinations and the expertise of Michel Reybier Hospitality.

For more information:
Media and investor relations: c/o Dynamics Group, Zurich
Marion Schihin, msc@dynamicsgroup.ch, + 41 79 705 88 15

About MRH Switzerland AG
MRH Switzerland AG is a hotel chain operating eleven hotels in Switzerland and abroad, under the Michel Reybier Hospitality brand. The hotels are located in premium destinations, including Zurich, Interlaken, Bern, Crans Montana, Zermatt, Davos, Flims and London. MRH Switzerland AG manages a portfolio with 1’180 rooms in operation, generating substantial annual traffic with 367’819 overnight stays. The chain employs 1’153 staff members. MRH Switzerland AG is a 100% subsidiary of AEVIS VICTORIA SA. www.michelreybierhospitality.com

About Michel Reybier Hospitality
For more than 20 years, Michel Reybier has been blazing the trail for a singular, highly contemporary vision of luxury and hospitality. Each of the Michel Reybier Hospitality destinations upholds his cherished values of excellence, authenticity and simplicity. Whether in a hotel, a villa or a private apartment, in the mountains or by the sea, in the countryside, in the heart of the vineyards or in the city… A sole requirement: namely exceptional places that throb with a distinctive emotion. A sole ambition: to share a refined art of living, dedicated above all else to our guests’ well-being and pleasure. This holistic approach is based on unforgettable experiences, where sport, food, wellness and passion form an inseparable whole. This approach is supported by the medical expertise of Nescens, whose ultimate goal is to ensure people live better, healthier lives for as long as possible. The promise of instilling meaning into each and every moment. www.michelreybierhospitality.com

About AEVIS VICTORIA SA
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS’s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (22.6%, directly and indirectly), a listed real estate company (INFRAC.SW) dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com


End of Media Release


2424870  30.10.2026 CET/CEST

Cantourage Further Expands Its Leading Market Position: Premium Producer LOT420 Receives EU-GMP Certification

Cantourage Group SE

/ Key word(s): Alliance/Statement

Cantourage Further Expands Its Leading Market Position: Premium Producer LOT420 Receives EU-GMP Certification

29.10.2026 / 10:23 CET/CEST

The issuer is solely responsible for the content of this announcement.


  • EU-GMP certification for craft cannabis producer: LOT420 is among the most sought-after suppliers in the European medical cannabis market.
  • Shorter delivery times, fresher products: LOT420’s cannabis flowers will reach European pharmacies even faster in the future.
  • Strategic competitive advantage: With the EU-GMP certification of another established premium producer, Cantourage strengthens its access to high-demand products and further consolidates its position in the European market.

Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01) and Canadian cannabis producer LOT420 are deepening their partnership following LOT420’s successful EU-GMP certification. Cantourage once again supported the certification process as sponsor and will benefit from exclusive access to LOT420’s popular cannabis products in Europe for the coming years. Following the successful EU-GMP certification of cultivation partner Green Karat just a few weeks ago, this latest milestone further demonstrates Cantourage’s regulatory expertise and strengthens its supply chain across the company’s European target markets.

Based southeast of Montreal, LOT420 is an established premium supplier in the European medical cannabis market. The producer specializes in high-quality craft cannabis, focusing on small-batch cultivation of non-irradiated cannabis flowers and cultivation techniques refined over many years. Cantourage first introduced LOT420’s products to the European market in 2023, where the company has since established itself as one of the most respected brands in the medical cannabis sector.

With LOT420’s EU-GMP certification, Cantourage is further strengthening its value chain and creating additional opportunities for importing dried cannabis flowers from Canada. As a result, LOT420’s premium flowers will be able to reach European pharmacies even faster after harvest. At the same time, shifting processing steps to EU-GMP-certified cultivation partners enables a more efficient cost structure, additional capacity and reduced operational risks. Cantourage is thus further expanding its position as a strategic partner for international premium producers seeking access to the European market.

“Together with us, LOT420 has become another long-standing partner to successfully achieve EU-GMP certification. The strong demand for LOT420’s products demonstrates just how important access to high-quality brands and products is to our market position. At the same time, by supporting our partners in obtaining certification, we are laying the foundation for more efficient supply chains, regulatory stability and further growth. This is another clear validation of our business model of enabling international cannabis producers to enter the European market as their regulatory and commercial partner,” says Philip Schetter, CEO of Cantourage Group SE.

Cantourage remains committed to systematically expanding its international network of EU-GMP-certified premium producers. The combination of strong partnerships, regulatory expertise and an increasingly flexible supply chain provides a solid foundation for further strengthening the company’s competitive position in Europe.

About Cantourage

Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and cannabis-based pharmaceuticals. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to access the growing European medical cannabis market faster, more easily and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In doing so, Cantourage consistently ensures compliance with the highest European pharmaceutical quality standards. The Company offers pharmaceutical-grade products across all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 – DE000A3DSV01 (ISIN).

 

 


29.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX
LEI Code: 3912003NCTLO6YHA9V48
EQS News ID: 2424552

 
End of News EQS News Service

2424552  29.10.2026 CET/CEST

Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026

Issuer: Immunic AG

/ Key word(s): Conference

Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026

29.10.2026 / 11:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day
on November 5, 2026

NEW YORK, October 29, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET.

In addition to members of Immunic’s management team, including Erik Lundgren, M.B.A., Chief Executive Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer, Hella Kohlhof, Ph.D., Chief Scientific Officer, and Jason Tardio, M.B.A., President & Chief Operating Officer, the event will feature presentations by two renowned experts in the treatment of MS and development of new therapies, Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University of Toronto, and Maria Pia Sormani, Ph.D., University of Genoa, Italy.

The group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression. Immunic management will highlight the potential expansion opportunity for lead investigational asset vidofludimus calcium (IMU-838) in progressive MS, including the clinical and scientific rationale supporting Immunic’s plans to initiate a Phase 3 progressive MS trial later in 2026. The differentiated profile of vidofludimus calcium, including its activity as a nuclear receptor-related 1 (Nurr1) activator and the potential neuroprotective effects associated with this mechanism, provides scientific rationale for its evaluation in progressive forms of MS.

The Virtual Progressive MS R&D Day will take place on Thursday, November 5, 2026, at 12:30 pm ET. To register for the event, please CLICK HERE.
 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is expected later in 2026. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
 

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

 

US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com

 

US Media Contact
Real Chemistry
media@imux.com


Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Drägerwerk AG & Co. KGaA: Dräger with higher net sales and earnings in the first nine months of 2026

Drägerwerk AG & Co. KGaA

/ Key word(s): Quarterly / Interim Statement/Quarter Results

Drägerwerk AG & Co. KGaA: Dräger with higher net sales and earnings in the first nine months of 2026

29.10.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Dräger with higher net sales and earnings in the first nine months of 2026

  • Order intake noticeably increased
  • Net sales growth in both divisions
  • EBIT increased by almost half – positive one-off effects from customs refunds

Lübeck – Drägerwerk AG & Co. KGaA increased its order intake by approximately EUR 79 million to around EUR 2,674 million in the first nine months of 2026 (9 months 2025: EUR 2,594.1 million). Net sales rose by approximately EUR 110 million to around EUR 2,454 million (9 months 2025: EUR 2,343.5 million). Earnings before interest and taxes (EBIT) went up by approximately EUR 35 million to EUR 111.8 million (9 months 2025: EUR 77.1 million). The EBIT margin improved to 4.6 percent (9 months 2025: 3.3 percent). EBIT included one-off effects from customs refunds.

“Demand for our ‘Technology for Life’ increased noticeably in the first nine months of 2026, and net sales also rose sharply. Earnings before interest and taxes were significantly above the prior-year level – due to the refund of U.S. customs paid in the prior year, but also thanks to the strong operating performance,” says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. “We are confident that we will achieve our annual targets.”

Order intake continues to rise
Group order intake rose by 3.6 percent (net of currency effects) to EUR 2,673.5 million in the first nine months of 2026 (9 months 2025: EUR 2,594.1 million). Germany was the largest growth driver, with a significant increase of around 15 percent. Demand also grew in the Europe, Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions. The Americas region recorded a decline. The main reason for this was the high prior-year level: In the second quarter of 2025, Dräger had received a major order for hospital infrastructure systems from Mexico.

In the medical division, order intake decreased by 3.5 percent (net of currency effects) to EUR 1,430.7 million (9 months 2025: EUR 1,495.5 million). Excluding the major order in the prior year, it would have remained almost stable (net of currency effects).

In the safety division, order intake increased significantly by 13.1 percent (net of currency effects) to EUR 1,242.8 million (9 months 2025: EUR 1,098.6 million). All regions and all product areas contributed to this development.

Strong net sales growth in both divisions
Group net sales increased by 5.3 percent (net of currency effects) to EUR 2,453.9 million in the first nine months of 2026 (9 months 2025: EUR 2,343.5 million). In the medical division, net sales increased by 4.4 percent (net of currency effects) to EUR 1,367.0 million (9 months 2025: EUR 1,322.3 million). In the safety division, net sales increased by 6.5 percent (net of currency effects) to EUR 1,087.0 million (9 months 2025: EUR 1,021.2 million).

Earnings significantly above the prior year
EBIT rose by almost half to EUR 111.8 million (9 months 2025: EUR 77.1 million). The EBIT margin also improved significantly by 1.3 percentage points to 4.6 percent (9 months 2025: 3.3 percent).

EBIT for the first nine months included one-off effects of EUR 27.9 million from customs refunds. Of this amount, EUR 7.8 million was attributable to the second quarter and EUR 20.1 million to the third quarter. Part of these refunds – a total of EUR 3.8 million – relates to customs expenses from the current fiscal year and is therefore earnings-neutral. At the same time, customs expenses of EUR 25.8 million were incurred in the U.S. in the current year, which are nonrefundable under current law.

The gross margin benefited from the customs refunds by around one percentage point. It increased by 1.7 percentage points to 46.8 percent (9 months 2025: 45.1 percent). Functional expenses in the first nine months of 2026 were 5.6 percent higher than the prior-year figure. The main drivers were personnel, logistics, and IT costs.

Business performance in the third quarter
In the third quarter, order intake increased by 7.0 percent (net of currency effects) to EUR 926.2 million (Q3 2025: EUR 856.1 million). The medical division recorded a decline of 3.0 percent (net of currency effects) to EUR 474.3 million (Q3 2025: EUR 484.7 million) due to weaker demand in the EMEA region. Demand in the Middle East declined significantly due to the ongoing Iran conflict. In the safety division, order intake increased by 20.2 percent (net of currency effects) to EUR 451.9 million (Q3 2025: EUR 371.4 million), thanks to good performance in all regions. Germany was the largest driver, with above-proportional growth of around 59 percent (net of currency effects), due in particular to a major order in the defense business.

Dräger’s net sales rose by 1.0 percent (net of currency effects) to EUR 850.8 million (Q3 2025: EUR 833.3 million). The gross margin increased by 1.8 percentage points to 47.5 percent (Q3 2025: 45.6 percent). EBIT came to EUR 48.0 million (Q3 2025: EUR 56.7 million). The EBIT margin amounted to around 5.6 percent (Q3 2025: 6.8 percent).

Forecast for 2026
For the current fiscal year, Dräger continues to expect an increase in net sales of 2.0 to 6.0 percent (net of currency effects) and an EBIT margin of 6.0 to 8.0 percent.

Further information is available in the financial report at www.draeger.com.

Disclaimer
This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Information on the financial indicators used (incl. alternative performance measures) can be found on our corporate website www.draeger.com in our Investor Relations section.

 

Key figures for the first nine months
(€ million)
9M 2026 9M 2025 Change Net of cur-
rency effects
         
Order intake 2,673.5 2,594.1 +3.1 +3.6
Germany 673.5 587.8 +14.6 +14.6
Europe, Middle East, and Africa 1,048.5 1,030.4 +1.7 +1.5
Americas 555.0 591.6 -6.2 -5.4
Asia-Pacific 396.5 384.4 +3.2 +6.0
         
Order intake, medical division 1,430.7 1,495.5 -4.3 -3.5
Order intake, safety division 1,242.8 1,098.6 +13.1 +13.1
         
Net sales 2,453.9 2,343.5 +4.7 +5.3
Germany 588.5 559.7 +5.2 +5.2
Europe, Middle East, and Africa 997.8 926.5 +7.7 +7.5
Americas 521.7 492.8 +5.9 +7.0
Asia-Pacific 345.9 364.6 -5.1 -2.3
         
Net sales, medical division 1,367.0 1,322.3 +3.4 +4.4
Net sales, safety division 1,087.0 1,021.2 +6.4 +6.5
         
EBIT 111.8 77.1    
EBIT margin 4.6 3.3    
Earnings after income taxes 73.8 45.5    
         
EBIT margin, medical division -0.7 -1.7    
EBIT margin, safety division 11.2 9.8    
         
Employees 16,716 16,684    
         
         
Key figures for the third quarter
(€ million)
Q3 2026 Q3 2025 Change Net of cur-
rency effects
         
Order intake 926.2 856.1 +8.2 +7.0
Germany 258.0 199.8 +29.1 +29.1
Europe, Middle East, and Africa 336.3 352.9 -4.7 -5.4
Americas 194.1 180.3 +7.6 +4.5
Asia-Pacific 137.9 123.1 +12.0 +10.5
         
Order intake, medical division 474.3 484.7 -2.2 -3.0
Order intake, safety division 451.9 371.4 +21.7 +20.2
         
Net sales 850.8 833.3 +2.1 +1.0
Germany 206.6 195.4 +5.7 +5.7
Europe, Middle East, and Africa 351.3 334.9 +4.9 +4.2
Americas 170.0 181.8 -6.5 -9.5
Asia-Pacific 122.9 121.1 +1.5 +0.3
         
Net sales, medical division 469.4 471.3 -0.4 -1.4
Net sales, safety division 381.3 362.0 +5.3 +4.1
         
EBIT 48.0 56.7    
EBIT margin 5.6 6.8    
Earnings after income taxes 33.6 35.9    
         
EBIT margin, medical division 1.0 2.3    
EBIT margin, safety division 11.4 12.6    
         
Employees 16,716 16,684    

 


29.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck
Germany
Phone: +49 (0)451 882-0
Fax: +49 (0)451 882-2080
E-mail: info@draeger.com
Internet: www.draeger.com
ISIN: DE0005550602, DE0005550636 (Vorzugsaktien)
WKN: 555060, 555063 (Vorzugsaktien)
Indices: SDAX, TecDax
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; London, Aquis, Stockholm, BX, SIX, Vienna Stock Exchange
LEI Code: 5493005UFVHY0PPNKD75
EQS News ID: 2424128

 
End of News EQS News Service

2424128  29.10.2026 CET/CEST

Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026

Evotec SE

/ Key word(s): Miscellaneous

Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026

29.10.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Hamburg, Germany, October 29, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call will be held in English.

Webcast details

Date:  Thursday, November 5, 2026

Time:  2.00 pm CET (1.00 pm GMT, 8.00 am EST)

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand version of the webcast will be available on our website: www.evotec.com.

Conference call details

To join the conference call, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialing in via phone is available under this link.

 

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

 

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

 


29.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Tradegate BSX; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Nasdaq
LEI Code: 529900F9KI6OYITO9B12
EQS News ID: 2422664

 
End of News EQS News Service

2422664  29.10.2026 CET/CEST

BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100

 

Basel, Switzerland. October 29, 2026, 7am CEST

  • BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).
  • RIV-CARE (NCT07431307), an open label Phase 2b clinical trial, aims to compare BV100 plus low-dose polymyxin B plus ceftazidime/avibactam, or plus cefiderocol to best-available-therapy (BAT) in multiple geographies with very high drug resistance levels.
  • RIV-CARE complements the ongoing Phase 3 RIV-TARGET trial of BV100, and is expected to broaden evidence based treatment in clinical practices, ahead of potential commercialisation.
  • RIV-CARE is conducted by ADVANCE-ID clinical trial network with funding support from Wellcome
  • Interim read-out is expected in H1 2027.

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today the first patient first visit in RIV-CARE, an open label Phase 2b differentiation trial of BV100.

RIV-CARE will enrol approximately 100 patients with suspected or confirmed hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). RIV-CARE aims to compare BV100 plus low-dose polymyxin B in combination with different background antibiotics (ceftazidime/avibactam or Cefiderocol) versus best available therapy across multiple geographies, to provide real-world evidence of clinical practice in settings with very high levels of drug resistance.

Dr. Glenn E Dale, Chief Development Officer of BioVersys: “CRABC remains amongst the most difficult to treat bacterial pathogens in hospitalized patients, with mortality reaching up to 50% globally due to very limited treatment options. Our RIV-CARE study allows us to bring a promising and novel treatment option, BV100, to patients who need it most. Importantly, RIV-CARE allows us to generate evidence exactly in settings with the highest resistance and greatest need.”

Professor David Paterson, Director of ADVANCE-ID, said: “Half of people with serious CRAB infections will die. Doctors desperately need new antibiotic options for treating these infections so we can lower the death rate. We hope that the RIV-CARE trial will help determine if BV100 plus low-dose polymyxin B is a safe and effective option for these infections.”

The last patient enrolled is anticipated towards end of 2027. RIV-CARE is conducted by the ADVANCE-ID clinical trial network, thanks to the generous contribution of Wellcome with SGD 22 million (c. USD 17m or CHF 14m). The non-dilutive funding from Wellcome offsets approximately 2/3 of the trial cost.

Dr. Florian von Groote-Bidlingmaier, Head of Clinical Research, Infectious Disease at Wellcome, said: “Antimicrobial resistance remains an urgent global health threat, and accelerating the development of new antibiotics into clinical use is a high priority. Partnerships like the one for this trial, that bring together industry, academia, clinical expertise and philanthropy, are vital for accelerating antibiotic R&D. The enrolment of the first patient in RIV-CARE is an important milestone, and it is exciting a potential new treatment is being evaluated in settings and communities already bearing a high burden of drug resistance.”

In September 2026, BV100 was granted Fast Track Designation by the US FDA, under the Qualified Infectious Disease Product (QIDP) Designation received in 2019. These designations make BV100 eligible for priority FDA review, increased communication on clinical trial design and data requirements, and a five-year extension of market exclusivity in the US.

BV100 is currently being studied in two clinical trials: the pivotal Phase 3 global registration trial, RIV-TARGET, which announced first patient first visit in April 2026, and the open-label Phase 2b differentiation trial, RIV-CARE. First submissions for regulatory approval are anticipated by mid-2028.

Dr. Marc Gitzinger, Chief Executive Officer of BioVersys, said: “We are pleased to report first patient first visit in RIV-CARE, our Phase 2b differentiation trial which is now recruiting in parallel with our RIV-TARGET Phase 3 trial. Together, RIV-TARGET and RIV-CARE represent a focused dual-trial strategy intended to support both regulatory approval and future commercial uptake of BV100. RIV-Target will deliver the pivotal data for registration, while RIV-CARE is designed to help answer the questions physicians will ask at the bed side, providing evidence on how BV100 performs in comparison with best available therapies in multiple geographies. The interim analysis of RIV-CARE, anticipated for H1 2027, will provide an important early read-out.”

RIV-CARE Phase 2b study design

RIV-CARE aims to evaluate the safety and efficacy of BV100 in combination with low dose polymyxin B plus ceftazidime/avibactam or cefiderocol in patients with suspected or confirmed CRABC nosocomial pneumonia (VABP and HABP) and BSI of non-urinary tract origin. This is an open-label study, and therefore, no blinding will be done.

The study is divided into two parts (Part A and Part B), recruiting in parallel. Approximately 90 patients will be recruited in Part A, and approximately 10 subjects will be recruited in Part B, with enrolment ending once Part A enrolment is complete.

In Part A, patients will be randomized 1:1:1, to one of the three treatment groups until the CRABC m-MITT population includes 30 evaluable subjects per group:

  • Group 1: 300 mg BV100 in combination with 500,000 IU (50 mg) polymyxin B infused over 2 hours every 12 hours (q12h), plus 2 g/0.5 g ceftazidime/avibactam, infused over 2 hours every 8 hours (q8h).
  • Group 2: 300 mg BV100 in combination with 500,000 IU (50 mg) polymyxin B infused over 2 hours every 12 hours (q12h), plus 2 g cefiderocol infused over 3 hours every 8 hours (q8h).
  • Group 3: Best Available Therapy, which is determined by the site for each individual patient according to local epidemiology and the patient’s antibiotic history.

Part B is a prospective multicentre, open label, non-randomized, additional single cohort to evaluate the PK, safety, and efficacy BV100 in combination with both low dose polymyxin B and cefiderocol in patients with CRABC ventriculitis or meningitis. After 14 days of treatment with BV100 and low dose polymyxin B, the BV100 therapy must be stopped, but patients may continue therapy with cefiderocol and best available additional therapy at the discretion of the investigator and as needed.

This study follows the successful completion of a Phase II study that showed that BV100 plus polymyxin B halved all-cause mortality compared with best available therapy, meaning 28-day mortality of 25% compared to 28-day mortality of 60% in best available therapy. In vitro, the combination of BV100 with low-dose polymyxin B and cefiderocol showed synergy and a reduction in the emergence of resistance, suggesting improved treatment outcomes in patients.

NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper

NVision Quantum

/ Key word(s): Miscellaneous

NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper

28.10.2026 / 17:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper

Partners with HyperLight to integrate thin-film molecular qubits onto advanced photonic integrated circuits, paving the way for a new architecture that delivers quantum computing at scale

Summary:

  • Announces publication of landmark peer-reviewed research in Nature validating the first individually addressable organic molecular qubit with photonic interface.
  • Advances a quantum computing architecture that combines compatibility with standard silicon foundry manufacturing with photonic connectivity to enable quantum computing at scale.
  • Establishes a strategic partnership with HyperLight to integrate thin-film molecular qubits directly onto advanced photonic integrated circuits. 

ULM, Germany – October 28, 2026 – NVision, a quantum technology company, announced the publication of landmark peer-reviewed research in Nature and a strategic partnership with HyperLight Corporation (“HyperLight”), an industry leader in thin-film lithium niobate (TFLN) photonics. The companies will integrate NVision’s thin-film molecular qubits directly onto advanced photonic integrated circuits (PICs). Together, these milestones establish a practical path to quantum computing at scale, using photonic connectivity to link quantum resources within and across processors. This opens a path toward millions of qubits on chips compatible with standard foundry manufacturing.

The Nature publication, A Single-Molecule Spin-Photon Interface, confirms the first ever individually addressable organic molecular spin-photon interface, which is the key ingredient for connecting stationary qubits with photons. Until now, molecular spins could not be individually and coherently controlled, preventing them from serving as true qubits. That barrier has now been broken: the core building block can be controlled at the single-molecule level. This opens a new path to scale, where molecular qubits can be deposited as thin films, much like OLED materials, directly on top of PICs, turning established photonic chip technology into a platform for scaling quantum computers.

“This proves what we’ve long believed: that organic chemistry offers a fundamentally better building block for quantum,” said Dr. Sella Brosh, CEO of NVision. “For years, the industry has been locked in a hardware race using modalities that would require decades and multi-billion-dollar proprietary fabrication facilities to achieve scale. With the creation of the world’s first manufacturable organic qubit, we now enter quantum’s molecular era, establishing a new architecture based on photonic connectivity from the get-go, with a clear path to scale through existing foundry infrastructure.”

Alongside the Nature publication, NVision announced a strategic partnership with HyperLight, a global leader in TFLN electro-optic PICs for high-bandwidth environments such as AI data centers, telecom and metro networks. The collaboration will integrate NVision’s molecular qubits as a thin film that can be deposited directly onto photonic chips, extending HyperLight’s TFLN Chiplet™ technology further into quantum applications. 

“Integrating NVision’s breakthrough molecular qubits onto our PICs unlocks a compelling path for scalable quantum hardware while showcasing the capabilities and versatility of HyperLight’s TFLN technology,” said Kevin Luke, co-founder and Head of Custom Development at HyperLight. “Photonic interconnectivity is essential for scaling quantum processors, and combining our optical chip infrastructure with manufacturable molecular thin films allows us to deliver high-density, chip-scale quantum connectivity that leverages decades of investment in semiconductor fabrication.”

The milestone directly advances NVision’s Photonic Integrated Quantum Circuits (PIQC) platform from foundational physics into commercial hardware development. Following initial chip deliveries from foundry partners, NVision is targeting a live demonstration of on-chip performance on PICs by the end of 2026. The company’s long-term commercial roadmap targets scaling to 1,000 physical qubits, progressing toward 1,000 logical, fault-tolerant qubits on chip by 2030 housed within a deployable data-center form factor.

Unlike monolithic quantum architectures that force qubits into tight physical proximity, which creates severe crosstalk, control complexity and thermal bottlenecks, NVision’s Photonic Integrated Quantum Circuit (PIQC) architecture uses optical links to decouple qubits from local spatial constraints. The engineered carbene molecules function at accessible cryogenic temperatures (2K – 4K) and emit photons natively at precise optical frequencies, enabling direct intra-chip and inter-chip quantum entanglement.

“Chemistry gives us a design freedom that semiconductor-based qubits, such as in silicon, simply do not have. By addressing quantum design at the molecular level, we can tune the performance that matters most, including quantum memory, gate speed and photon emission, within a single molecule,” said Dr. Ilai Schwartz, CTO of NVision. “Because our qubits interact directly with light from the start, we achieve connectivity without proximity, making photonic networking a foundational capability of our platform rather than something we have to add later.”

To achieve this milestone, NVision combined large-scale computational screening with targeted synthesis, evaluating more than 150 candidate molecules, out of which 40 were synthesized in the laboratory. The resulting carbene system is engineered to interface directly with photons, making photonic connectivity a practical building block for scalable architectures. Crucially, the platform tolerates up to 70% photon loss, enabling reliable operation with standard silicon photonics rather than requiring ultra-low-loss, specialized optical infrastructure.

First prototype integrated chips resulting from the collaboration are expected in Q4 2026. For detailed technical specifications, architectural white papers, and access to the peer-reviewed Nature study (DOI: 10.1038/s41586-026-11147-6), read  Designed, not Discovered: A Molecule Built to Be a Qubit.

Prineha Narang, Partner, DCVC:

“At DCVC, we’re excited to back NVision because we believe its molecular qubit platform has the potential to accelerate the roadmap for quantum computing as a whole. Using molecules as the building blocks of quantum hardware is a visionary approach, one that could make qubits easier to manufacture, scale, and industrialize. This is the kind of innovation that could bring us closer to realizing quantum computing’s promise, including the discovery of new materials and molecules.”

Peter Barrett, Co-Founder and General Partner, Playground Global:

“The ability to read and write spin states with light is a breakthrough in our ability to control the quantum nature of nature. NVision brings manufacturability and the design freedom of chemistry to quantum computing, with molecular qubits that could be integrated directly onto photonic chips. It opens a remarkable possibility: designing molecules to build computers that can, in turn, help us design entirely new forms of matter.” 

Avi Eyal, Managing Partner, Entrée Capital:

“From the start, the NVision team chose to solve quantum’s scaling problem at the molecular level rather than brute-force it with ever-larger fabrication plants. The announcement today puts NVision among the few companies with a credible, manufacturable path to quantum computing at scale. Few teams anywhere combine this depth in quantum physics, organic chemistry and photonics, and we’re proud to support them as they move from foundational science to commercial hardware.”

Christian Reitberger, Founding Partner, Matterwave Ventures:

“It is exciting to see NVision’s quantum metabolic imaging work being complemented by a computing modality that will benefit rational drug design, thus enabling a fast design to metabolic testing loop. That the carbene-photon interface can be realized on existing commercial PIC technology is crucial for a capital efficient path towards a useful computing system.”

Marco Allegretti, Senior Partner of AI Fund at CDP Venture Capital:

“This important milestone reflects both the strength of NVision’s vision and the outstanding execution demonstrated by its team. The publication in Nature and the partnership with HyperLight mark a significant validation of the company’s technological journey and further strengthen the investment thesis that convinced us to support NVision from its earliest stages.”

Dr. Itamar Sivan, Co-Founder and CEO, Quantum Machines:

“NVision’s achievement introduces an exciting new building block for quantum computing, bringing together molecular qubits and photonic connectivity with a vision for scale. Quantum Machines’ control platform brings these elements together, helping turn pioneering science into working quantum systems. We’re delighted to contribute to this milestone and to work alongside NVision as they build toward scalable quantum computers.”
 

About NVision Quantum Technologies 

NVision is a full stack quantum technology company focused on healthcare, with deep expertise in engineering and controlling the quantum properties of organic molecules. This approach underpins both its POLARIS platform, which enables real-time measurement of metabolism on standard MRI systems, and its quantum computing platform, Photonic Integrated Quantum Circuits (PIQC, pronounced “Pixie”). Together, these capabilities are helping bridge the gap between understanding disease and delivering effective therapies. Founded in 2015 and headquartered in Ulm, Germany, NVision is backed by Playground Global, DCVC, Entrée Capital, Matterwave/b2venture, Lauder Partners, Pathena Investments, The European Investment Bank and others. Learn more at nvision-quantum.com.

About HyperLight

HyperLight delivers high-performance integrated photonics solutions based on thin-film lithium niobate technology. The company combines the electro-optic advantages of TFLN with scalable manufacturing, test, and integration to enable next-generation optical engines for AI data centers, telecom and metro networks, and emerging photonics markets.

 

Media Contact:

For high-resolution images or any other inquiries, please contact press@nvision-quantum.com


28.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2424016  28.10.2026 CET/CEST

Eckert & Ziegler Receives GMP Certificate for Actinium-225

Eckert & Ziegler SE

/ Key word(s): Regulatory Approval

Eckert & Ziegler Receives GMP Certificate for Actinium-225

28.10.2026 / 14:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Braunschweig, Germany, 28 October 2026. Eckert & Ziegler Therapeutics GmbH, wholly owned subsidiary of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Actinium-225 (Ac-225). The certification by the competent German authority confirms that production meets the stringent requirements of Good Manufacturing Practice (GMP) and facilitates the use of the radioisotope for the investigational treatment of patients.

Actinium-225 is widely regarded as one of the most promising alpha emitters for use in targeted radiopharmaceutical applications. This is reflected in both the increasing number of clinical trials investigating this radionuclide and the advancement of clinical programs into later-stage development.

“This regulatory milestone is the decisive step that turns our production capability into a supply commitment the field can build their clinical and commercial programs on,” said Dr. Gunnar Mann, Member of the Executive Board and responsible for Operations at Eckert & Ziegler’s Medical Segment. “We have quickly moved from first production runs in our upscaled process to GMP grade routine manufacturing. This is what improving supply security looks like in practice.”

The overall production route uses cyclotron-based irradiation of Radium-226 (Ra-226) at the Řež facilities of the Czech Academy of Sciences’ Nuclear Physics Institute (Ústav jaderné fyziky, “UJF”). Afterwards the irradiated material is processed at Eckert & Ziegler’s Braunschweig site to obtain GMP grade Ac-225. Production activities at both sites are supported by custom-engineered hot cell systems from Isotope Technologies Dresden GmbH, Eckert & Ziegler’s hot cell division.

The proprietary process set up by Eckert & Ziegler ensures that the cyclotron-based production of Ac-225 results in an isotopic profile with long-lived impurities such as Actinium-227 and Thorium-229 kept to a minimum, thereby meeting the expectations of nuclear medicine physicians and radiopharmacists alike.

Secured access to Radium-226
Accessing Ra-226 as the precursor material is one of the principal bottlenecks in global Ac-225 production. To alleviate the pressure on its supply chain, Eckert & Ziegler has integrated the repurposing of Ra-226 legacy sources into its sourcing strategy. Additionally, the production method recovers unconverted Ra-226 after irradiation and reintroduces it to the process, allowing the material to be used across multiple cycles. This helps reduce dependency on constrained global Ra-226 inventories while limiting radioactive waste, contributing to more predictable output volumes and costs for both radioisotope supply and CDMO programs.

Capacity expansion in Asia and North America
The newly opened production facility of Eckert & Ziegler’s joint venture Qi Kang Medical Technology (Changzhou) Co., Ltd. in Jintan, China is intended to become the first site in the country dedicated to the production of Ac-225 on a commercial scale. This second phase is planned to be realized after initial operations start in early 2027.
In addition, further capacity expansion can be considered at Eckert & Ziegler’s established radiopharmaceutical manufacturing site near Boston, MA, USA, as well as in Germany, to support the future commercial supply of Ac-225-based medicinal products.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com


28.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 391200EUDABLUKXCKG48
EQS News ID: 2416898

 
End of News EQS News Service

2416898  28.10.2026 CET/CEST